Dublin, Dec. 14, 2017 -- The "Gastrointestinal / GI Stent Market by Type, Materia, Disease, End User - Global Forecast to 2022" report has been added to Research and Markets' offering.
The global gastrointestinal stent market is projected to reach USD 452.6 Million by 2022 from USD 353.4 Million in 2017, at a CAGR of 5.1% during the forecast period.
Market growth can be attributed to the growth in the geriatric population, increasing preference for minimally invasive surgeries, rising prevalence of GI cancers and other digestive diseases, and changing lifestyles.
The report analyzes the global gastrointestinal stent market, by product, material, disease type, end user, and region. Based on product, the biliary stents segment accounted for the largest share of global market in 2016. This can be attributed to the high prevalence of pancreatic cancer and biliary diseases as well as the growth in the number of surgical procedures for the treatment of these diseases.
The major complications associated with the implementation of gastrointestinal stents include stent misplacement or displacement, bleeding, obstruction, perforation, stent fracture or collapse, and infection. Bacterial colonization is a major factor leading to plastic stent occlusion, which results in sludge formation and luminal obstruction. Covered gastrointestinal stents generally prevent obstruction from tumor ingrowth with a covering membrane but have a higher migration rate. These complications associated with gastrointestinal stenting are limiting their adoption.
Boston Scientific Corporation (US) dominated the global gastrointestinal stent market in 2016. The company focuses on increasing its share in the market by strategically investing in R&D activities. For instance, in 2016, the company invested USD 920 million in R&D, as compared to USD 876 million in 2015. The company's focus on improving its speed and performance through new capabilities, processes, and advanced innovative technologies; its expanding commercial presence globally; and its cost-reduction initiatives help it to accelerate its growth in the market. In 2016, the company's revenue reported a growth of 12% as compared to the previous year. The company is also focusing on expanding its business in emerging countries. It reported a growth of 22% in its annual revenue in China, which is one of the largest emerging markets in the developing world.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Gastrointestinal Stent Market: Overview
4.2 Asia Pacific: Gastrointestinal Cancer Stents Market, By Product and Country
4.3 Global Market, By Country
4.4 Global Market, By Disease Type
4.5 Regional Mix: Global Market
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Prevalence of Gastrointestinal Cancers and Other Digestive Diseases
5.2.1.2 Increasing Geriatric Population
5.2.1.3 Growing Preference for Minimally Invasive Procedures
5.2.1.4 Changing Lifestyles
5.2.2 Restraint
5.2.2.1 Complications Associated With Gastrointestinal Stent Implementation
5.2.3 Opportunities
5.2.3.1 Development of Biodegradable and Drug-Eluting Gastrointestinal Stents
5.2.3.2 Emerging Markets
5.3 Reimbursement Scenario in the US
5.4 Regulatory Analysis
6 Gastrointestinal Stent Market, By Product
6.1 Introduction
6.2 Biliary Stents
6.3 Colonic Stents
6.4 Duodenal Stents
6.5 Pancreatic Stents
6.6 Esophageal Stents
7 Gastrointestinal Stent Market, By Material
7.1 Introduction
7.2 Self-Expanding Metal Stents
7.2.1 Nitinol Stents
7.2.2 Stainless Steel Stents
7.2.3 Other Metal Stents
7.3 Plastic Stents
8 Gastrointestinal Stent Market, By Disease Type
8.1 Introduction
8.2 Biliary Diseases
8.3 Gastrointestinal Cancer
8.3.1 Colorectal Cancer
8.3.2 Pancreatic Cancer
8.3.3 Stomach Cancer
8.3.4 Esophageal Cancer
8.4 Inflammatory Bowel Diseases
9 Gastrointestinal Stent Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Ambulatory Surgery Centers
10 Gastrointestinal Stent Market, By Region
11 Competitive Landscape
12 Company Profiles
- Becton, Dickinson and Company
- Boston Scientific
- C.R. Bard
- Cantel Medical
- Conmed
- Cook Group
- Diagmed Healthcare
- Ella-CS
- Endo-Flex
- M.I. Tech
- Merit Medical Systems
- Micro-Tech (Nanjing)
- Olympus
- Taewoong Medical
For more information about this report visit https://www.researchandmarkets.com/research/zdthvq/global?w=12
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Stents


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Washington Post Publisher Will Lewis Steps Down After Layoffs
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



